Study tests if one bone drug dose is as good as many for breast cancer patients
NCT ID NCT03664687
Summary
This trial aimed to find the best schedule for giving zoledronate, a drug that strengthens bones and may help prevent cancer from spreading there. It compared giving just one dose versus giving a dose every six months for three years to over 200 patients with early-stage breast cancer. The main goal was to see if the simpler, single-dose schedule worked just as well for preventing bone problems and was easier to run in clinics.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Markham Stouffville Hospital
Markham, Ontario, L3P 7P3, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8M2, Canada
-
Southlake Regional Health Centre
Newmarket, Ontario, L3Y 2P9, Canada
-
William Osler Health System, Brampton Civic Hospital
Brampton, Ontario, L6R 3J7, Canada
Conditions
Explore the condition pages connected to this study.